SSTR2 and neoplasm: Despite the successful clinical outcomes of radiotracers targeting SSTR2 or FAP, single-receptor recognition may limit their sensitivity for disease detection, especially in early stages, due to tumor heterogeneity and relatively low receptor expression density [17].